Bluebird Bio Withdraws Zynteglo From Germany Over Pricing
Germany Is The Only Country Where the Gene Therapy Was Marketed
Executive Summary
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
You may also be interested in...
ICER Report Assumes $2.8m Price For Libmeldy As Orchard Gears Up For US Debut
The drug-pricing watchdog gave the gene therapy for metachromatic leukodystrophy an “A” grade for use in presymptomatic patients receiving the therapy, which already is approved in Europe.
Cell And Gene Therapy Companies Fear More Market Delays From EU’s Single Review Plans
Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.
BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany
BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.